FDA grants priority review to Agios' mitapivat for sickle cell disease
Tweet Send to a Friend
Agios Pharmaceuticals (Nasdaq: AGIO) announced that the U.S. Food and Drug Administration has accepted its supplemental New Drug Application (sNDA) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


